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Abstract
Background:  Since contradictory results have been reported, we reanalysed the 77C→ G
transition in exon 4 of the protein-tyrosine phosphatase receptor-type C (PTPRC also known as
CD45) in a large cohort of German MS patients and controls. Different isoforms of the protein are
expressed, depending on alternative splicing of exons 4 (CD45RA), 5 (CD45RB) and 6 (CD45RC)
(CD45RO, exons 4–6 spliced out). The 77C→ G transition does not change the amino acid
sequence, but it is probably part of a motif necessary for splicing leading to the isoform CD45RA.
The expression of CD45RA is increased in 77C/G heterozygous individuals. The aim of the study
was to clarify the importance of the PTPRC 77C→ G transition in our German cohort of MS
patients.
Methods:  PCR products of exon 4 were digested using endonuclease MspI. The resulting
restriction fragments of the wildtype C allele are 198 and 62 bp in length. In the G allele an
additional restriction site is present yielding fragments of 114 and 84 bp.
Results: The G allele was identified in 10 of the 347 controls (1.4%) and in 7 of 454 MS patients
(0.8%; Table 1). No homozygous individuals were found either in the control or in the patient
group. Genetic association between the PTPRC 77C→ G transition and MS susceptibility was
excluded in the MS cohort. In addition, subgrouping patients according to differences in the clinical
course of MS or according to HLA-DRB1*15 status did not yield significant differences.
Conclusions:  The 77C→ G transition in exon 4 of the PTPRC gene may contribute to MS
susceptibility only in very few families, if at all, but it is not relevant for the majority of MS cases,
including virtually all German patients.
Background
Multiple sclerosis (MS) is an autoimmune disease affect-
ing the central nervous system by demyelination. Both en-
vironmental and genetic components contribute to the
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development of MS. An efficient strategy to elucidate the
genetic background of MS is to analyse single nucleotide
polymorphisms (SNPs) in respective candidate genes.
Since contradictory results have been reported recently
[1–3], we analysed the 77C→ G transition in exon 4 of the
protein-tyrosine phosphatase receptor-type C (PTPRC
also known as CD45) [4]. PTPRC is localized on chromo-
some 1q31-q32 and consists of 35 exons. The gene en-
codes a 180–220 kDa glycoprotein expressed on
leukocytes and hematopoietic progenitors [4]. This recep-
tor is involved in T and B cell activation and in signal
transduction by regulating protein-tyrosine kinases. Be-
cause of this involvement in immunological reactions, the
gene is a candidate for MS predisposition. The protein ex-
ists in multiple isoforms, depending on alternative splic-
ing of exons 4 (CD45RA), 5 (CD45RB) and 6 (CD45RC)
(CD45RO, exon 4–6 spliced out). The 77C→ G transition
does not change the amino acid sequence, but it is proba-
bly part of a motif necessary for splicing of CD45RA. The
expression of CD45RA is increased in 77C/G hetero-
zygous individuals [1].
Methods
Peripheral blood samples from more than 400 healthy
blood donors were obtained with their informed consent,
and provided by the department of transplantation and
immunology of the University Hospital Eppendorf (Ham-
burg, Germany). The mean age of the healthy donors was
39.3 ± 11.47 years. The male/female ratio was 1.4 ± 0.5.
More than 800 unrelated MS patients attending the De-
partment of Neurology, University clinics of Bochum and
Göttingen (Germany) participated in this study. The
male/female ratio was 1.7 ± 0.47, the mean age at MS on-
set was 29.9 ± 9.63 years. 55.3% of all clinically diagnosed
MS patients exhibited a relapsing/remitting course of MS
(RRMS), 25.8% developed secondary progressive MS
(SPMS) and 18.9% were characterized by primary pro-
gressive MS (PPMS). The mean EDSS (expanded disability
status scale) of all MS patients was 4.2 ± 2.31, of PPMS 5.8
± 1.91 and of RRMS+SPMS 3.9 ± 2.25 [5].
Polymerase chain reaction (PCR) of exon 4 of PTPRC was
carried out in a final volume of 12.5 µl with 50 ng of DNA,
200 µM dNTP, 1 U Taq Polymerase and PTPRC exon 4
specific primers (forward, 5'-ATTTATTTTGTCCTTCTC-
CCA-3' and reverse, 5'-GTTAACAACTTTTGTGTGCCAAC-
3'). PCR cycling started with initial denaturation for 5
minutes at 94°C. The annealing temperature of the first
cycle was 61°C, second cycle 58°C and remaining 26 cy-
cles 55°C. The annealing time was 1 minute. Extension
was performed at 72°C for 1 minute (final extension 5
minutes). PCR products were digested using endonucle-
ase MspI according to the manufacturer's recommenda-
tion. Digested DNA was electrophoresed on 1.5% agarose
gels. The restriction fragments of the wildtype C allele
were 198 and 62 bp in length. The G allele harbors an ad-
ditional restriction site so that the 198 bp fragment is di-
gested into 114 and 84 bp (Figure 1).
Results
The rare G allele was present in 10 of the 347 controls
(1.4%) and in 7 of 454 MS patients (0.8%; Table 1). There
were no homozygous individuals either in the control or
patient groups. Genetic association between the PTPRC
77C→ G transition and MS susceptibility was excluded in
the MS cohort. In addition, subgrouping patients accord-
ing to differences in the clinical course of MS (RRMS,
SPMS, PPMS) or according to HLA-DRB1*15 status did
not yield significant differences.
Table 1: Allele frequency of the 77C→ G transition in PTPRC. Ho-
mozygosity was not observed.
C allele (%) G allele (%)
Controls (N = 347) 684 (98.6) 10 (1.4)
MS patients (N = 454) 901 (99.2) 7 (0.8)*
RRMS (N = 219) 435 (99.3) 3 (0.7)
SPMS (N = 92) 182 (98.9) 2 (1.1)
PPMS (N = 70) 139 (99.3) 1 (0.7)
HLA-DRB1*15 MS patients (N = 161) 320 (99.4) 2 (0.6)
* p = 0.2. RRMS = relapsing remitting course of MS; SPMS = second-
ary progressive course of MS; PPMS = primary progressive course of 
MS
Figure 1
Restriction fragment length polymorphism (RFLP) analysis of
PTPRC exon 4 77C→ G; M=pUC19 DNA marker (501, 489,
404, 331, 242, 190, 147, 111, 110, 67 bp)BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/3
Page 3 of 3
(page number not for citation purposes)
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.com
Discussion
This result contradicts the findings of Jacobsen et al.[1]
who demonstrated an association of the mutation with
MS in 3 families. Barcellos et al.[2] and Vorechovsky et al.
[3] excluded MS association as well. However, as yet un-
known polymorphisms in the PTPRC gene may contrib-
ute to MS susceptibility.
Conclusions
In conclusion, the PTPRC exon 4 77C→ G transition
seems to contribute to MS susceptibility only in a few fam-
ilies, if at all, but it is not relevant for the majority of MS
cases, also not in virtually all German patients.
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